Streetbeat News

Assets

SPY

Goolsbee has stated that there is a close attention being paid to long term rates. The SPY ETF, which tracks the S&P 500, could be affected by changes in these rates.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:08 pm

CORR

CorEnergy Infrastructure Trust has projected its capital expenditures to be between $11.5M and $12.5M. The company also expects its adjusted EBITDA to be in the range of $24M to $26M.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:05 pm

FUSN

Fusion Pharmaceuticals reported Q3 cash and investments of $207.3M, which is expected to be sufficient to fund operations into the second quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:54 pm

SNSE

Sensei Biotherapeutics reported Q3 losses of $(0.28) per share, beating the analyst consensus estimate of $(0.34) by 17.65%. This is a 36.36% increase over losses from the same period last year. The company's cash, cash equivalents and marketable securities of $72M are expected to fund operations into the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:42 pm

VERV

Verve Therapeutics reported that it ended Q3 with $485.2M in cash, cash equivalents, and marketable securities. The company expects this to be sufficient to fund its operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:27 pm

ARVN

Arvinas has announced that its Q3 cash, cash equivalents, restricted cash, and marketable securities total around $1B. The company believes this is sufficient to fund its planned operating expenses and capital expenditure requirements until 2026.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:24 pm

DTIL

Precision BioSciences reported a Q3 cash balance of $122.2M, which is expected to provide an extended cash runway through the end of 2025.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:19 pm

TRDA

Entrada Therapeutics has announced that it has sufficient cash runway through 2025, with $354M in cash, cash equivalents, and marketable securities. The company's financial position appears strong, which may positively impact its stock performance.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:17 pm

STOK

As of September 30, 2023, Stoke Therapeutics reported having $214.7M in cash, cash equivalents, and marketable securities. This is anticipated to fund the company's operations until the end of 2025.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:13 pm

RYTM

Rhythm Pharmaceuticals has announced that its current cash on-hand of $299.3 million is sufficient to fund its planned operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:12 pm